Imaging Drugs Make Jump To Devices In New Decision By FDA
Executive Summary
After losing the recent Genus Medical Technologies court case, the US FDA will begin transitioning certain imaging agent drugs to devices. Because user-fee deadlines for drugs and generics are approaching, the agency says firms should pay those fees now and ask for a refund after the transition.
You may also be interested in...
Ophthalmic Dispensers Recommended Class I Designation By FDA Panel
The FDA’s Ophthalmic Devices Panel approved a Class I designation for ophthalmic dispensers, which were reclassified from drugs to devices after the Genus v. FDA decision.
MDUFA V Passed By US House Health Subcommittee
The user fee package was among several health-related bills that the subcommittee took up on Wednesday.
Genus Triumphs Over FDA In Barium Sulfate Product Classification Suit
The decision limits US FDA discretion in determining how to regulate products that seem to meet both drug and device standards.